BTIG Research Downgrades Juno Therapeutics (JUNO), 0 Analysts Bullish Penn West Petroleum Ltd (USA) (PWE)

June 8, 2017 - By Clifton Ray

Among 13 analysts covering Juno Therapeutics Inc (NASDAQ:JUNO), 6 have Buy rating, 0 Sell and 7 Hold. Therefore 46% are positive. Juno Therapeutics Inc has $73 highest and $24.0 lowest target. $38.67’s average target is 71.87% above currents $22.5 stock price. Juno Therapeutics Inc had 27 analyst reports since July 22, 2015 according to SRatingsIntel. The firm has “Hold” rating by Standpoint Research given on Thursday, October 29. Standpoint Research initiated Juno Therapeutics Inc (NASDAQ:JUNO) on Monday, August 24 with “Buy” rating. The firm earned “Outperform” rating on Thursday, June 2 by Raymond James. Suntrust Robinson downgraded the shares of JUNO in report on Friday, November 25 to “Hold” rating. Citigroup initiated the shares of JUNO in report on Thursday, February 25 with “Buy” rating. The company was downgraded on Friday, July 8 by JP Morgan. The company was initiated on Thursday, February 2 by Wedbush. The stock has “Buy” rating by Maxim Group on Friday, August 5. The stock has “Buy” rating by Maxim Group on Wednesday, November 23. The stock of Juno Therapeutics Inc (NASDAQ:JUNO) earned “Mkt Perform” rating by Raymond James on Tuesday, December 6.

Among 6 analysts covering Penn West Petroleum (NYSE:PWE), 0 have Buy rating, 2 Sell and 4 Hold. Therefore 0 are positive. Penn West Petroleum had 9 analyst reports since November 6, 2015 according to SRatingsIntel. The stock of Penn West Petroleum Ltd (USA) (NYSE:PWE) earned “Underperform” rating by Raymond James on Monday, June 6. The company was downgraded on Tuesday, April 11 by Altacorp. The company was upgraded on Monday, June 27 by RBC Capital Markets. As per Monday, June 6, the company rating was downgraded by JP Morgan. The firm has “Sector Underperform” rating by IBC given on Friday, November 6. The rating was downgraded by Raymond James to “Market Perform” on Thursday, April 13. RBC Capital Markets maintained Penn West Petroleum Ltd (USA) (NYSE:PWE) rating on Friday, November 6. RBC Capital Markets has “Sector Perform” rating and $1.40 target. The firm has “Outperform” rating by Raymond James given on Monday, June 13. As per Friday, July 22, the company rating was upgraded by Barclays Capital. See Penn West Petroleum Ltd (USA) (NYSE:PWE) latest ratings:

13/04/2017 Broker: Raymond James Old Rating: Outperform New Rating: Market Perform Downgrade
11/04/2017 Broker: Altacorp Old Rating: Outperform New Rating: Sector Perform Downgrade

Investors sentiment decreased to 1.04 in Q4 2016. Its down 0.36, from 1.4 in 2016Q3. It dropped, as 33 investors sold Juno Therapeutics Inc shares while 37 reduced holdings. 23 funds opened positions while 50 raised stakes. 45.31 million shares or 3.22% more from 43.89 million shares in 2016Q3 were reported. Aperio Gp Ltd Liability Corporation holds 0% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO) for 13,850 shares. Invesco Limited holds 0% or 18,500 shares. Washington National Bank & Trust owns 11 shares for 0% of their portfolio. Rockefeller Fincl Service Incorporated reported 0% in Juno Therapeutics Inc (NASDAQ:JUNO). Blackrock Investment Mgmt Ltd Liability Corp owns 31,662 shares or 0% of their US portfolio. 33,674 were reported by Profund Advsr Ltd Limited Liability Company. California Pub Employees Retirement Systems reported 74,300 shares. Caprock Gru reported 23,923 shares. Ellington Grp Lc holds 0.03% or 10,500 shares in its portfolio. Metropolitan Life Insurance New York holds 0% or 4,065 shares. Baillie Gifford And has invested 0.34% in Juno Therapeutics Inc (NASDAQ:JUNO). Blackrock Advsr Limited Liability Co invested 0% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO). Us Retail Bank De holds 0.01% in Juno Therapeutics Inc (NASDAQ:JUNO) or 94,100 shares. Rock Springs Capital Mgmt Lp holds 0.25% in Juno Therapeutics Inc (NASDAQ:JUNO) or 197,001 shares. Fincl Architects reported 0% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO).

Juno Therapeutics, Inc. is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The company has market cap of $2.60 billion. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. It currently has negative earnings. The Company’s product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas.

About 4,497 shares traded. Juno Therapeutics Inc (NASDAQ:JUNO) has declined 39.85% since June 8, 2016 and is downtrending. It has underperformed by 56.55% the S&P500.

The stock decreased 8.39% or $0.12 during the last trading session, reaching $1.31. About shares traded. Penn West Petroleum Ltd (USA) (NYSE:PWE) has risen 130.51% since June 8, 2016 and is uptrending. It has outperformed by 113.81% the S&P500.